K
89.20
16.22 (22.23%)
| Previous Close | 72.98 |
| Volume | 2,320,104 |
| Price / Earnings (Forward) | 57.02 |
| Price / Sales | 7.11 |
| Price / Book | 8.70 |
| 52 Weeks Range |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Kiniksa Pharmaceuticals Interna | Mixed | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | -0.25 |
Select this tab to load the latest available analysis.
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |